Saturday, July 2, 2022

Fair Share

My brilliant and creative colleagues, Bill Tomlinson, Bonnie Nardi, Daniel Stokols, Ankita Raturi, and I are pleased our article, "Returning ecological wealth to nonhuman species through design: the case for ecosystemas", has been published in Ecology and Society (27(2): 34).  Here is the abstract:

Human population and energy use have increased rapidly in recent centuries. This growth has relied on Homo sapiens appropriating ecosystem services previously shared more equitably with many other species. Envisioning this process as a transfer of ecological wealth among species provides a framework within which to examine human activities. We use this framework to critique the broad endeavor of design, and in particular human-computer interaction design, as it has been pursued by human civilization over the past several decades. We offer a conceptual tool, the ecosystema, that may help enable design processes to support the redistribution of ecological wealth to nonhuman species. The ecosystema is based on the concept of personas: distilled representations of particular user groups that are a key part of many design processes. The ecosystema construct is analogous to a persona, but at the level of an entire ecosystem rather than of a particular human population. This construct could help discern ecosystem level impacts and enable them to influence design processes more effectively. Ecosystemas also may afford greater leverage for effectively managing current environmental crises than existing anthropocentric design approaches.

Saturday, June 18, 2022

Biotechnology Patent Law Top Ten Of 2020

Brilliant legal eagle, Kevin Noonan, and I collaborate each year on an article covering what we consider to be the top ten United States biotechnology patent law judicial decisions of that year.  Our article, "Biotechnology Patent Law Top Ten of 2020: Valeant Victorious, Falling Eagle, and Successful Slayback", was recently published in the Texas A & M Journal of Property Law (citation:  8 Tex. A&M J. Prop. L. 409-472 (2022)).  Download the article here for free.  Here is the abstract:

One of the most famous trilogies ever published ends with the hero, Frodo the hobbit, sailing aboard an elven ship from the Grey Havens of Middle Earth to the Undying Lands in the west. Despite this being the third in a series of “Biotechnology Patent Law Top Ten” articles, in this trilogy the world of biotechnology patent law has no leading hero, no ultimate destination, nor any final resolution of issues.

To the contrary, this exciting area of law and technology continues to witness winners and losers in myriad battles across a wide doctrinal theatre of legal war with no end in sight. It is true that some in biotechnology view the uncertainty surrounding the scope of patentable biotechnological subject matter under 35 U.S.C. § 101 as a metaphorical ring they wish the fires of Mount Doom could destroy (or at least clarified by the United States Supreme Court). Others consider the ongoing patent disputes between the University of California, University of Vienna, and Emmanuelle Charpentier (often referred to collectively as “CVC”) and the Broad Institute of MIT and Harvard to be as consequential as the Battle of the Five Armies. We will not even try to compare the endless Abbreviated New Drug Application (“ANDA”) struggles between brand pharmaceutical companies and their upstart generic drug firm rivals using a literary device derived from The Lord of the Rings.3 Suffice it to say that biotechnology patent law will continue to vigorously evolve, and we plan to continue our coverage of its evolution beyond the current trilogy of Biotechnology Patent Law Top Tens.

As in previous years, we admit it was difficult to choose precisely ten top biotechnology patent law decisions. There are certainly otherswe did not include that warrant close attention for their reasonings, rules, and future implications. Nevertheless, both we and our readers can count, so we have done our best to select what we consider to be the top ten biotechnology patent law decisions of 2020. We discuss these decisions [in the article].

To avoid falling behind, consider reading the 2020 Top Ten promptly, because publication of our Biotechnology Patent Law Top Ten of 2021 is imminent.

Saturday, March 5, 2022

Burke's Bees

 The Burke Museum of Natural History and Culture is a hidden gem in Seattle.  Nestled in the northwesternmost corner of the University of Washington campus, right next to the School of Law, its collections and research efforts are both excellent.  As Visiting Professor at the School of Law back in 2011, I would often cross the 100m to the Burke to explore its latest exhibits.  The Burke has now assured its excellence by appointing the brilliant and inspiring bee expert Dr. Gabriela Chavarria as Executive Director.